Mar. 16 at 2:25 PM
$CRVO Something I learned over the weekend from the K-10 report, and why the upcoming investor talks are important:
With a public float below
$75M, CervoMed is currently subject to the SEC’s “baby shelf rule,” which limits the amount of capital it can raise through shelf offerings over a 12-month period.
Besides other factors they focus more an partnerships, debts (currently no long-term debt at all) and other finacing structures.
So it is a mixed information, can't be easily diluted to fiance trial 3, but also needs still financing. The good thing in my observations: In biotech, the biggest driver of the stock is still clinical trial results, not financing rules. If the outlook is good enough, money will follow.
